ARTICLE | Clinical News
Oxytrol oxybutynin patch regulatory update
February 4, 2013 8:00 AM UTC
FDA approved Oxytrol oxybutynin patch from Actavis for OTC use in women to treat overactive bladder (OAB). Marketing partner Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) plans to launch the ...